BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 24836441)

  • 1. Erlotinib: early clinical development in brain cancer.
    Addeo R; Zappavigna S; Parlato C; Caraglia M
    Expert Opin Investig Drugs; 2014 Jul; 23(7):1027-37. PubMed ID: 24836441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
    Halatsch ME; Schmidt U; Behnke-Mursch J; Unterberg A; Wirtz CR
    Cancer Treat Rev; 2006 Apr; 32(2):74-89. PubMed ID: 16488082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
    Raizer JJ
    J Neurooncol; 2005 Aug; 74(1):77-86. PubMed ID: 16078112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma.
    Gao Q; Lei T; Ye F
    Expert Opin Investig Drugs; 2013 Aug; 22(8):1023-40. PubMed ID: 23731170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.
    Lassman AB; Rossi MR; Raizer JJ; Abrey LE; Lieberman FS; Grefe CN; Lamborn K; Pao W; Shih AH; Kuhn JG; Wilson R; Nowak NJ; Cowell JK; DeAngelis LM; Wen P; Gilbert MR; Chang S; Yung WA; Prados M; Holland EC
    Clin Cancer Res; 2005 Nov; 11(21):7841-50. PubMed ID: 16278407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
    Mellinghoff IK; Wang MY; Vivanco I; Haas-Kogan DA; Zhu S; Dia EQ; Lu KV; Yoshimoto K; Huang JH; Chute DJ; Riggs BL; Horvath S; Liau LM; Cavenee WK; Rao PN; Beroukhim R; Peck TC; Lee JC; Sellers WR; Stokoe D; Prados M; Cloughesy TF; Sawyers CL; Mischel PS
    N Engl J Med; 2005 Nov; 353(19):2012-24. PubMed ID: 16282176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenetic pathways leading to glioblastoma multiforme: association between gene expressions and resistance to erlotinib.
    Löw S; Vougioukas VI; Hielscher T; Schmidt U; Unterberg A; Halatsch ME
    Anticancer Res; 2008; 28(6A):3729-32. PubMed ID: 19189657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer.
    Nakata A; Gotoh N
    Expert Opin Ther Targets; 2012 Aug; 16(8):771-81. PubMed ID: 22762482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor pathway gene expressions and biological response of glioblastoma multiforme cell lines to erlotinib.
    Halatsch ME; Löw S; Hielscher T; Schmidt U; Unterberg A; Vougioukas VI
    Anticancer Res; 2008; 28(6A):3725-8. PubMed ID: 19189656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts.
    Gadji M; Crous AM; Fortin D; Krcek J; Torchia M; Mai S; Drouin R; Klonisch T
    Eur J Pharmacol; 2009 Dec; 625(1-3):23-30. PubMed ID: 19836372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents.
    Minniti G; Muni R; Lanzetta G; Marchetti P; Enrici RM
    Anticancer Res; 2009 Dec; 29(12):5171-84. PubMed ID: 20044633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Iyer R; Bharthuar A
    Expert Opin Pharmacother; 2010 Feb; 11(2):311-20. PubMed ID: 20088749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
    D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
    Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer.
    Zhang J; Yu J; Sun X; Meng X
    Cancer Lett; 2014 Aug; 351(1):6-12. PubMed ID: 24861428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
    Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
    Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of tyrosine kinase inhibitors in clinical breast cancer.
    Agrawal A; Gutteridge E; Gee JM; Nicholson RI; Robertson JF
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S135-44. PubMed ID: 16113090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment.
    Guo G; Narayan RN; Horton L; Patel TR; Habib AA
    Curr Cancer Drug Targets; 2017; 17(3):297-302. PubMed ID: 28004613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Di Maio M; Gridelli C; Normanno N; Perrone F; Ciardiello F
    J Cell Physiol; 2005 Dec; 205(3):355-63. PubMed ID: 15895392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells.
    Struve N; Riedel M; Schulte A; Rieckmann T; Grob TJ; Gal A; Rothkamm K; Lamszus K; Petersen C; Dikomey E; Kriegs M
    Oncotarget; 2015 Oct; 6(32):33867-77. PubMed ID: 26418954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.